We previously reviewed the application prospects of inhibitors targeting the PI3K/AKT/mTOR signaling pathway in PCNSL and found that the efficacy of inhibitors as single agents in the treatment of patients with PCNSL might be limited, and it might be difficult to achieve long-term control of the disease with this approach [50]. This evidence concerns the gene MTOR and primary central nervous system lymphoma.